Telbivudine, Adefovir dipivoxil — Competitive Intelligence Brief

Telbivudine, Adefovir dipivoxil (Telbivudine, Adefovir dipivoxil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor. Area: Virology / Hepatology.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor Hepatitis B virus DNA polymerase / reverse transcriptase Virology / Hepatology Small molecule

Target snapshot

Telbivudine, Adefovir dipivoxil (Telbivudine, Adefovir dipivoxil) — Third Affiliated Hospital, Sun Yat-Sen University. Telbivudine and adefovir dipivoxil are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting viral DNA polymerase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Telbivudine, Adefovir dipivoxil TARGET	Telbivudine, Adefovir dipivoxil	Third Affiliated Hospital, Sun Yat-Sen University	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor	Hepatitis B virus DNA polymerase / reverse transcriptase
Adefovir (ADV)	Adefovir (ADV)	Bristol-Myers Squibb	phase 3	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus DNA polymerase / reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Pill	Emtricitabine / Tenofovir Disoproxil Pill	Fundacion IDEAA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Nanfang Hospital, Southern Medical University · 1 drug in this class
3. Third Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
4. University of Washington · 1 drug in this class